RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model

Mol Ther. 2002 Dec;6(6):770-82. doi: 10.1006/mthe.2002.0800.

Abstract

Effective suppression of HIV-1 replication requires inhibition of critical viral target molecules. Tat and Rev are indispensable regulatory factors for HIV-1 replication, whereas Env mediates virus entry by direct interaction with surface receptor CD4 and coreceptor CCR5 or CXCR4. Anti-HIV-1 tat-rev and env ribozymes and Rev aptamers were previously demonstrated to provide relatively long-term protection against HIV-1 infection in vitro. However, further improvements in these constructs for clinical application in a stem-cell-based gene therapy setting requires in vivo characterization. Toward this end, we introduced these constructs into CD34(+) hematopoietic progenitor cells by retrovirus-mediated gene transduction. Ribozyme- and aptamer-transduced CD34(+) cells differentiated normally into multiple lineages of erythroid and myeloid progenies in a colony-forming unit assay. Macrophages that differentiated from the transduced CD34(+) cells expressed anti-tat-rev and -env ribozymes and Rev aptamers and displayed their normal characteristic surface markers CD14, CD4, and CCR5. Using the SCID-hu mouse in vivo human thymopoiesis model, we demonstrated that ribozyme- and aptamer-transduced CD34(+) cells retained their normal capacity to reconstitute human fetal thymus and liver tissue (thy/liv) grafts. Reconstitution by ribozyme- and aptamer-transduced CD34(+) cells reached levels of up to 87% based on HLA surface marker staining. Differentiated thymocytes derived from reconstituted grafts expressed anti-tat-rev and -env ribozymes and Rev aptamers and showed significant resistance to HIV-1 infection upon challenge. Analysis of reconstituted thymocytes by hybridization revealed an average of 0.4 to 2 copies of vector sequences per cell. Southern analysis of proviral integration junctions in progeny thymocytes demonstrated that the human thy/liv grafts were reconstituted by a few primitive hematopoietic stem cells. These results highlight the utility of RNA-based anti-HIV-1 gene therapeutic approaches and their preclinical testing in a surrogate animal model harboring human tissue.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigens, CD34 / metabolism
  • Base Sequence
  • Cell Differentiation
  • Cell Line
  • Cell Lineage
  • Cytokines / pharmacology
  • Disease Models, Animal*
  • Gene Expression Regulation, Viral
  • Gene Products, rev / genetics
  • Gene Products, tat / genetics
  • Genetic Therapy / methods*
  • HIV Infections / genetics*
  • HIV Infections / therapy*
  • HIV-1 / genetics
  • HIV-1 / physiology
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / metabolism
  • Hematopoietic Stem Cells / virology
  • Humans
  • Liver Transplantation
  • Macrophages / immunology
  • Macrophages / metabolism
  • Mice
  • Mice, SCID
  • Mitogens / pharmacology
  • RNA, Catalytic / genetics
  • RNA, Catalytic / metabolism
  • RNA, Catalytic / therapeutic use*
  • Receptors, CXCR4 / metabolism
  • Thymus Gland / cytology
  • Thymus Gland / embryology
  • Thymus Gland / immunology
  • Thymus Gland / virology
  • rev Gene Products, Human Immunodeficiency Virus
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • Antigens, CD34
  • Cytokines
  • Gene Products, rev
  • Gene Products, tat
  • Mitogens
  • RNA, Catalytic
  • Receptors, CXCR4
  • rev Gene Products, Human Immunodeficiency Virus
  • tat Gene Products, Human Immunodeficiency Virus